All the news Showing 10 of 62 articles from: Antiviral therapyGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Expanded vaccination and treatment could help eliminate hepatitis B worldwide Liz Highleyman / 28 April 2015 While universal infant hepatitis B virus (HBV) vaccination has already led to major advances in reducing new infections in some settings, further expansion of prevention and treatment are needed to significantly reduce HBV ... Cancer drug shows promise as cure for hepatitis B Science Daily / 21 April 2015 Arrowhead initiates phase 2b trial for potential HBV drug Healio Hepatology / 14 April 2015 WHO issues its first hepatitis B treatment guidelines World Health Organization / 12 March 2015 Adding pegylated interferon to tenofovir improves odds of HBsAg loss in hepatitis B patients Liz Highleyman / 05 February 2015 People with chronic hepatitis B virus (HBV) infection are more likely to experience favourable treatment response, as indicated by hepatitis B surface antigen (HBsAg) loss, if they add pegylated interferon to tenofovir – ... Entecavir and tenofovir work well for people with drug-resistant hepatitis B virus Liz Highleyman / 04 February 2015 A combination of entecavir plus tenofovir effectively suppressed hepatitis B virus (HBV) in people with resistance to other antivirals, according to results from the European ENTEBE study presented at the American Association for ... FDA places Arrowhead Hepatitis B drug on partial hold, shares plunge Reuters / 13 January 2015 Tekmira Pharmaceuticals and OnCore Biopharma Announce Merger Agreement to Create Leading Global Hepatitis B Virus Company Tekmira press release / 13 January 2015 Tenofovir continues to suppress hepatitis B virus for eight years Keith Alcorn / 05 December 2014 Most people with chronic hepatitis B who are treated with tenofovir for eight years continued to maintain viral suppression, researchers reported at the American Association for the Study of Liver Diseases (AASLD) Liver ... Entecavir + tenofovir works well for people with hepatitis B who have had prior treatment failure Liz Highleyman / 28 November 2013 A dual regimen of entecavir (Baraclude) plus tenofovir (Viread) for 48 weeks led to virological response and was generally well-tolerated among people with chronic hepatitis B who had experienced treatment failure with ... ← Prev1...34567Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Noticeboard Email bulletins News feeds